Research Progress of Ubiquitin Proteasome Inhibitors in Acute Myeloid Leukemia.
10.3881/j.issn.1000.503X.14299
- Author:
Fang-Nan XIAO
1
;
Ming-Ying ZHANG
1
;
Yuan ZHOU
1
Author Information
1. State Key Laboratory of Experimental Hematology,National Clinical Research Center for Blood Diseases,Institute of Hematology & Blood Diseases Hospital,CAMS and PUMC,Tianjin 300020,China.
- Publication Type:Journal Article
- Keywords:
acute myeloid leukemia;
ubiquitin-proteasome system;
ubiquitin-proteasome system inhibitor
- MeSH:
Humans;
Proteasome Inhibitors/therapeutic use*;
Ubiquitin/metabolism*;
Proteasome Endopeptidase Complex/metabolism*;
Ubiquitination;
Leukemia, Myeloid, Acute/drug therapy*
- From:
Acta Academiae Medicinae Sinicae
2022;44(5):868-875
- CountryChina
- Language:Chinese
-
Abstract:
Ubiquitin-proteasome system (UPS) plays an essential role in eukaryotic protein cycle,the dysregulation of which can lead to tumorigenesis.Increased activities of UPS have been observed in the patients with cancers including leukemia.UPS inhibitors can kill cancer cells by affecting ubiquitin-ligating enzyme E3,deubiquitinase,and protein degradation active sites of UPS.Therefore,UPS inhibitors have emerged as an important therapy for treating hematological malignancies,while they are rarely applied in the treatment of acute myeloid leukemia.This paper summarizes the research progress in the inhibitors affecting the protein ubiquitination at different stages of acute myeloid leukemia,aiming to provide new clues for the clinical treatment of acute myeloid leukemia.
